Replies to post #1141 on ImClone Systems Inc (formerly IMCL)

[Imclonian]

one would also need to know if the trials are looking at squamous NSCLC patients or non squamous NSCLC patients.

[jbog]

Pfizer,


The final confirmation of the pfizer lung trial dropped the RR from the original reported 37% to 22% but the OS still was nice.

If it's close to Erby in OS it'll be the winner because I'm not so sure how long patients are going to want the skin tox of efgr treatment. 10 to 20 months of skin tox has to be unbearable.